Cytokinetics, Incorporated
CYTK
Rangering i aksjer
#2306
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aksjekurs
$62.08
Sist synkronisert: 2026-10-19
Markedsverdi
$8.63B
Endring (1 dag)
0.21%
Endring (1 år)
4.60%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
P/S-forhold for Cytokinetics, Incorporated (CYTK)
P/S-forhold per October 2026 TTM: 124.27
Ifølge Cytokinetics, Incorporated sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 124.27. Ved slutten av 2023 hadde selskapet et P/S-forhold på 1.07K.
P/S-historikk for Cytokinetics, Incorporated fra 2000 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 124.27 | -56.42% |
| 2024 | 285.13 | -73.36% |
| 2023 | 1.07K | 2,359.57% |
| 2022 | 43.51 | -12.55% |
| 2021 | 49.76 | 107.19% |
| 2020 | 24.02 | 5.63% |
| 2019 | 22.74 | 108.24% |
| 2018 | 10.92 | -63.75% |
| 2017 | 30.12 | 560.39% |
| 2016 | 4.56 | -67.68% |
| 2015 | 14.11 | 131.57% |
| 2014 | 6.09 | 5.34% |
| 2013 | 5.78 | -39.02% |
| 2012 | 9.49 | -44.17% |
| 2011 | 16.99 | -67.35% |
| 2010 | 52.04 | 2,440.73% |
| 2009 | 2.05 | -81.93% |
| 2008 | 11.33 | -31.41% |
| 2007 | 16.52 | -81.13% |
| 2006 | 87.59 | 318.89% |
| 2005 | 20.91 | 38.64% |
| 2004 | 15.08 | 418.48% |
| 2003 | 2.91 | 18.20% |
| 2002 | 2.46 | -8.85% |
| 2001 | 2.70 | 0.00% |
| 2000 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -91.94% |
US
|
|
| 40.55 | -67.37% |
US
|
|
| 3.96 | -96.81% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -91.84% |
NL
|
